Helland Arne, Muller Sébastien, Spigset Olav, Krabseth Hege-Merete, Hansen Miriam, Skråstad Ragnhild Bergene
Department of Clinical Pharmacology, St. Olav University Hospital, NO-7006 Trondheim, Norway.
Institute of Clinical and Molecular Medicine, Norwegian University of Science and Technology, NO-7491 Trondheim, Norway.
J Anal Toxicol. 2025 Feb 15;49(2):65-72. doi: 10.1093/jat/bkae097.
Dexamphetamine, lisdexamphetamine, and methylphenidate are central stimulant drugs widely used to treat attention-deficit/hyperactivity disorder (ADHD), but poor adherence may lead to treatment failure, and the drugs are also subject to misuse and diversion. Drug analysis in oral fluid may thus be useful for monitoring adherence and misuse. We measured drug concentrations in oral fluid and urine after controlled dosing to investigate detection windows and evaluate the chosen cutoffs. Healthy volunteers ingested single oral doses of 10 mg dexamphetamine (n = 11), 30 mg lisdexamphetamine (n = 11), or 20 mg methylphenidate (n = 10), after which they collected parallel oral fluid and urine samples every 8 h for 4-6 days. Amphetamine (analytical cutoff, oral fluid: 1.5 ng/mL; urine: 50 ng/mL), methylphenidate (oral fluid: 0.06 ng/mL), and ritalinic acid (urine: 500 ng/mL) were analyzed using fully validated chromatographic methods. The median time from ingestion to the last detection in oral fluid was 67 ± 4.9 h (lisdexamphetamine) and 69 ± 8.8 h (dexamphetamine) for amphetamine and 36 ± 2.5 h for methylphenidate. This was comparable to urine (77 ± 5.1 h for lisdexamphetamine, 78 ± 4.5 h for dexamphetamine, and 41 ± 2.4 h for ritalinic acid). The interindividual variability in detection times was large, probably in part due to pH-dependent disposition. Using a logistic regression approach, we found similar detection rates as a function of time since intake in urine and oral fluid with the chosen cutoffs, with a high degree of probability for detection at least 24 h after intake of a low therapeutic dose. This demonstrates the usefulness of oral fluid as a test matrix to assess adherence to ADHD medications, provided that the analytical method is sensitive, requiring a cutoff as low as 0.1 ng/mL for methylphenidate. Detection windows similar to those in urine may be achieved for amphetamine and methylphenidate in oral fluid.
右旋苯丙胺、赖氨酸右旋苯丙胺和哌甲酯是广泛用于治疗注意力缺陷多动障碍(ADHD)的中枢兴奋剂药物,但依从性差可能导致治疗失败,且这些药物还存在滥用和转移的问题。因此,口腔液中的药物分析可能有助于监测依从性和滥用情况。我们在控制给药后测量了口腔液和尿液中的药物浓度,以研究检测窗口并评估所选的截断值。健康志愿者单次口服10毫克右旋苯丙胺(n = 11)、30毫克赖氨酸右旋苯丙胺(n = 11)或20毫克哌甲酯(n = 10),之后他们每8小时平行采集口腔液和尿液样本,持续4 - 6天。使用经过充分验证的色谱方法分析苯丙胺(分析截断值,口腔液:1.5纳克/毫升;尿液:50纳克/毫升)、哌甲酯(口腔液:0.06纳克/毫升)和ritalinic酸(尿液:500纳克/毫升)。从摄入到口腔液中最后一次检测的中位时间,苯丙胺为67±4.9小时(赖氨酸右旋苯丙胺)和69±8.8小时(右旋苯丙胺),哌甲酯为36±2.5小时。这与尿液情况相当(赖氨酸右旋苯丙胺为77±5.1小时,右旋苯丙胺为78±4.5小时,ritalinic酸为41±2.4小时)。检测时间的个体间变异性很大,可能部分归因于pH依赖性处置。使用逻辑回归方法,我们发现对于所选截断值,尿液和口腔液中自摄入后随时间变化的检测率相似,摄入低治疗剂量后至少24小时检测的概率很高。这表明,只要分析方法灵敏,口腔液作为评估ADHD药物依从性的检测基质是有用的,哌甲酯的截断值低至0.1纳克/毫升。口腔液中苯丙胺和哌甲酯的检测窗口可能与尿液中的相似。